Iteos Therapeutics Inc Quick Ratio (ITOS) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Iteos Therapeutics Inc   (NASDAQ: ITOS)

Iteos Therapeutics Inc 's Quick Ratio

ITOS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 6.54 below Iteos Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 52 other companies have achieved higher Quick Ratio than Iteos Therapeutics Inc in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 204 to 408.

Explain Quick Ratio?
How much Cash & cash equivalents ITOS´s has?
What are ITOS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ITOS Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change 32.7 % 30.02 % 7.52 % 37.47 % 33.69 %
Y / Y Cash & cash equivalent Change -9.77 % 15.86 % -7.01 % -18.42 % -4.67 %
Quick Ratio MRQ 6.54 7.64 7.57 8.2 9.62
ITOS's Total Ranking # 408 # 204 # 174 # 342 # 305
Seq. Current Liabilities Change 15.74 % 4.2 % 9.67 % 0.33 % 13.4 %
Seq. Cash & cash equivalent Change -0.95 % 5.2 % 1.22 % -14.45 % 27.19 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 53
Healthcare Sector # 214
Overall Market # 408


Quick Ratio Statistics
High Average Low
32.93 11.59 1.66
(Sep 30 2020)   (Sep 30 2021)




Financial Statements
Iteos Therapeutics Inc 's Current Liabilities $ 79 Millions Visit ITOS's Balance sheet
Iteos Therapeutics Inc 's Cash & cash equivalent $ 515 Millions Visit ITOS's Balance sheet
Source of ITOS's Sales Visit ITOS's Sales by Geography


Cumulative Iteos Therapeutics Inc 's Quick Ratio

ITOS's Quick Ratio for the trailling 12 Months

ITOS Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 25.92 % 25.63 % 22.36 % 12.57 % -22.85 %
Y / Y Cash & cash equivalent TTM Growth -6.14 % -4.79 % -14.09 % -15.43 % -16.18 %
Quick Ratio TTM 7.43 8.22 8.46 8.79 9.96
Total Ranking TTM # 2774 # 2802 # 2782 # 2775 # 2812
Seq. Current Liabilities TTM Growth 7.69 % 6.64 % 1.97 % 7.52 % 7.45 %
Seq. Cash & cash equivalent TTM Growth -2.69 % 3.55 % -1.83 % -5.13 % -1.28 %

Quick ratio ranking by company, industry and sector >> Back to ITOS Financial Strength Comparisons >> Go to Compare ITOS Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2025 to $78.81 millions, cumulative Quick Ratio decreased to 7.43 below the Iteos Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 140 other companies have achieved higher Quick Ratio than Iteos Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 2774, from total ranking during the twelve months ending first quarter 2025 at 2802.

Explain Quick Ratio?
How much Cash & cash equivalents ITOS´s has?
What are ITOS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 141
Healthcare Sector # 811
Within the Market # 2774


trailing twelve months Quick Ratio Statistics
High Average Low
25.4 10.06 2.7
(Mar 31 2021)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Crispr Therapeutics Ag  16.49 $ 1,721.237  Millions$ 104.362  Millions
Apogee Therapeutics Inc   16.02 $ 505.420  Millions$ 31.551  Millions
Cidara Therapeutics Inc   15.80 $ 510.575  Millions$ 32.318  Millions
Qiagen N v   15.12 $ 1,098.918  Millions$ 72.656  Millions
Inhibikase Therapeutics Inc   14.89 $ 87.666  Millions$ 5.887  Millions
Maze Therapeutics Inc   13.29 $ 264.541  Millions$ 19.900  Millions
Genenta Science S p a   13.29 $ 31.527  Millions$ 2.372  Millions
Imagenebio Inc   13.06 $ 95.642  Millions$ 7.324  Millions
In8bio Inc   13.04 $ 13.226  Millions$ 1.014  Millions
Pharmacyte Biotech Inc   12.67 $ 13.440  Millions$ 1.061  Millions
Protara Therapeutics Inc  12.52 $ 122.216  Millions$ 9.761  Millions
Taysha Gene Therapies Inc   12.34 $ 312.761  Millions$ 25.349  Millions
Cargo Therapeutics Inc   12.08 $ 252.567  Millions$ 20.908  Millions
Aura Biosciences Inc   11.94 $ 177.311  Millions$ 14.852  Millions
Kalaris Therapeutics Inc   11.56 $ 88.426  Millions$ 7.651  Millions
Entera Bio Ltd   11.28 $ 10.858  Millions$ 0.963  Millions
Prokidney Corp   10.77 $ 294.728  Millions$ 27.359  Millions
Engene Therapeutics Inc   10.68 $ 201.913  Millions$ 18.913  Millions
Titan Pharmaceuticals Inc   10.66 $ 2.803  Millions$ 0.263  Millions
Century Therapeutics inc   10.43 $ 155.843  Millions$ 14.948  Millions
Acumen Pharmaceuticals Inc   10.42 $ 143.369  Millions$ 13.753  Millions
Neumora Therapeutics Inc   10.41 $ 217.588  Millions$ 20.897  Millions
Leonabio Inc   10.00 $ 29.823  Millions$ 2.981  Millions
Cullinan Therapeutics Inc   9.96 $ 265.482  Millions$ 26.664  Millions
Solid Biosciences Inc   9.95 $ 268.110  Millions$ 26.950  Millions
Denali Therapeutics Inc   9.87 $ 898.952  Millions$ 91.057  Millions
Alpha Cognition Inc.  9.71 $ 39.405  Millions$ 4.058  Millions
Anavex Life Sciences Corp   9.48 $ 101.164  Millions$ 10.669  Millions
Molecular Partners Ag  9.37 $ 103.269  Millions$ 11.027  Millions
Tscan Therapeutics Inc   8.71 $ 218.045  Millions$ 25.034  Millions

Date modified: 2026-09-08T15:22:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.